Protodioscin (NSC-698 796): Its Spectrum of Cytotoxicity Against Sixty Human Cancer Cell Lines in an Anticancer Drug Screen Panel

Abstract

Protodioscin (NSC-698 796) is a furostanol saponin isolated from the rhizome of Dioscorea collettii var. hypoglauca (Dioscoreaceae), a Chinese herbal remedy for the treatment of cervical carcinoma, carcinoma of urinary bladder and renal tumor for centuries. To systematically evaluate its potential anticancer activity, protodioscin was tested for cytotoxicity in vitro against 60 human cancer cell lines in the NCI’s (National Cancer Institute, USA) anticancer drug screen. As a result, protodioscin was cytotoxic against most cell lines from leukemia and solid tumors in the NCI’s human cancer panel, especially selectively against one leukemia line (MOLT-4), one NSCLC line (A549/ATCC), two colon cancer lines (HCT-116 and SW-620), one CNS cancer line (SNB-75), one melanoma line (LOX IMVI), and one renal cancer line (786 - 0) with GI₅₀ ≤ 2.0 μM. In the general view of mean graphs, leukemia, colon cancer and prostate cancer are the most sensitive subpanels, while ovarian cancer is the least sensitive subpanel. Based on an analysis of COMPARE computer program with protodioscin as a seed compound, no compounds in the NCI’s anticancer drug screen database have cytotoxicity patterns (mean graphs) similar to those of protodioscin, indicating that a potential novel mechanism of anticancer action is involved.

Cytotoxicity - protodioscin - NCI’s anticancer drug screen - NSC-698 796 - Dioscorea collettii var. hypoglauca - Dioscoreaceae

References

• 1 Kobayashi H, Namikoshi M, Yoshimoto T, Yokochi T. A screening method for antimitotic and antifungal substances using conidia of Pyricularia oryzae, modification and application to tropical marine fungi.  Journal of Antibiotics. 1996;  49 873-9
• 2 Hu K, Dong A J, Yao X S, Kobayashi H, Iwasaki S. Antineoplastic agents; I. Three spirostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca .  Planta Medica. 1996;  62 573-5
• 3 Hu K, Dong A J, Yao X S, Kobayashi H, Iwasaki S. Antineoplastic agents; II. Four furostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca .  Planta Medica. 1997;  63 161-5
• 4 Hu K, Dong A J, Yao X S, Kobayashi H, Iwasaki S. A furostanol glycoside from rhizomes of Dioscorea collettii var. hypoglauca .  Phytochemistry. 1997;  44 1339-42
• 5 Hu K, Kobayashi H, Dong A J, Iwasaki S, Yao X S. A new pregnane glycoside from Dioscorea collettii var. hypoglauca .  Chinese Chemical Letters. 1998;  9 739-42
• 6 Hu K, Dong A J, Kobayshi H, Iwasaki S, Jing Y K, Yao X S. A new pregnane glycoside from Dioscorea collettii var. hypoglauca .  Journal of Natural Products. 1999;  62 299-301
• 7 Boyd M R. Status of the NCI preclinical antitumor drug discovery screen. In: Cancer: Principles and practice of oncology updates. De Vita VT Jr, Hellman S, Rosenberg SA, editors Philadelphia: Lippincott; 1989: 1-12
• 8 Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo , Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.  Journal of National Cancer Institute. 1991;  83 757-66
• 9 Grever M R, Schepartz S A, Chabner B A. The National Cancer Institute cancer drug discovery and development program.  Seminars in Oncology. 1992;  19 622-36
• 10 Alley M C, Scudiero D A, Monks A P, Hursey M L, Czerwinski M J, Fine D L, Abbott B J, Mayo J G, Shoemaker R H, Boyd M R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.  Cancer Research. 1988;  48 589-601
• 11 Skehan P, Storeng R, Scudiero D A, Monks A P, McMahon J, Vistica D T, Warren J T, Bokesch H, Kenney S, Boyd M R. New colorimetric cytotoxicity assay for anticancer drug screening.  Journal of National Cancer Institute. 1990;  82 1107-12
• 12 Rubinstein L V, Shoemaker R H, Paull K D, Simon R M, Tosini S, Skehan P, Scudiero D A, Monks A P, Boyd M R. Comparison of in vitro anticancer drug screening data generated with a tertrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.  Journal of National Cancer Institute. 1990;  82 1113-8
• 13 Paull K D, Shoemaker R H, Hodes L, Monks A P, Scudiero D A, Rubinstein L V, Plowman J, Boyd M R. Display and analysis of pattern of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm.  Journal of National Cancer Institute. 1989;  81 1088-92
• 14 Weinstein J N, Kohn K W, Grever M R, Viswanadhan V N, Rubinstein L V, Monks A P, Scudiero D A, Welch L, Koutsoukos A D, Chiausa A J, Paull K D. Neural computing in cancer drug development: Predicting mechanism of action.  Science. 1992;  258 447-51
• 15 Boyd M R, Paull K D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen.  Drug Development Research. 1995;  34 91-109
• 16 Bates S E, Fojo A T, Weinstein J N, Myers T G, Alvarez M, Paull K D, Chabner B A. Molecular targets in the National Cancer Institute drug screen.  Journal of Cancer Research and Clinical Oncology. 1995;  121 495-500
• 17 Monks A P, Scudiero D A, Johnson G S, Paull K D, Sausville E A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.  Anti-Cancer Drug Design. 1997;  12 533-41
• 18 Weinstein J N, Myers T G, O’Connor P M, Friend S H, Fornace A J, Kohn K W, Fojo T, Bates S E, Rubinstein L V, Anderson N L, Buolamwini J K, van Osdol W W, Monks A P, Scudiero D A, Sausville E A, Zaharevitz D W, Bunow B, Viswanadhan V N, Johnson G S, Wittes R E, Paull K D. An information-intensive approach to the molecular pharmacology of cancer.  Science. 1997;  275 343-9